RECATICIMAB

Approval Year

Name

Type

Language

SHR-1209

Preferred Name

English

RECATICIMAB

Official Name

English

IMMUNOGLOBULIN G1 (256-TYROSINE,258-THREONINE,260-GLUTAMIC ACID), ANTI-(NEURAL APOPTOSIS-REGULATED PROTEINASE 1) (HUMAN-MUS MUSCULUS MONOCLONAL HRP00130 .GAMMA.1-CHAIN), DISULFIDE WITH (3-VALINE,5-SERINE,49-SERINE,66-ASPARTIC ACID) HUMAN-MUS MUSCULUS MON

Common Name

English

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENSPCSK9 (PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, NEURAL APOPTOSIS-REGULATED CONVERTASE 1, NARC1, NARC-1, PROPROTEINE CONVERTASE 9, PC9)), MONOCLONAL ANTIBODY (RECATICIMAB)

Common Name

English

IMMUNOGLOBULIN G1 (256-TYROSINE,258-THREONINE,260-GLUTAMIC ACID), ANTI-(PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9) (HUMAN-MUS MUSCULUS MONOCLONAL HRP00130 .GAMMA.1-CHAIN), DISULFIDE WITH (3-VALINE,5-SERINE,49-SERINE,66-ASPARTIC ACID) HUMAN-MUS MUSCUL

Common Name

English

recaticimab [INN]

Common Name

English

SHR1209

Code

English

SHR 1209 [WHO-DD]

Common Name

English

Code System Code Type Description

FDA UNII

20IE6M67UX